Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Receivables (2020 - 2025)

Historic Change in Receivables for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to -$3.9 million.

  • RxSight's Change in Receivables fell 112093.75% to -$3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year decrease of 11166.57%. This contributed to the annual value of $9.8 million for FY2024, which is 512.6% up from last year.
  • Per RxSight's latest filing, its Change in Receivables stood at -$3.9 million for Q3 2025, which was down 112093.75% from -$2.9 million recorded in Q2 2025.
  • In the past 5 years, RxSight's Change in Receivables ranged from a high of $5.0 million in Q4 2023 and a low of -$3.9 million during Q3 2025
  • Its 5-year average for Change in Receivables is $1.1 million, with a median of $1.3 million in 2022.
  • As far as peak fluctuations go, RxSight's Change in Receivables skyrocketed by 56645.37% in 2024, and later crashed by 112093.75% in 2025.
  • Over the past 5 years, RxSight's Change in Receivables (Quarter) stood at $504000.0 in 2021, then surged by 283.93% to $1.9 million in 2022, then surged by 160.31% to $5.0 million in 2023, then dropped by 7.05% to $4.7 million in 2024, then plummeted by 183.45% to -$3.9 million in 2025.
  • Its Change in Receivables stands at -$3.9 million for Q3 2025, versus -$2.9 million for Q2 2025 and $928000.0 for Q1 2025.